| LP434996-7 | Injury Risk | DIVISORS | |
| LP434997-5 | CMS - Number of Venous and Arterial Ulcers | COMPONENT | 1 |
| LP434998-3 | CMS - Other Ulcers, Wounds and Skin Problems | COMPONENT | 1 |
| LP434999-1 | CMS - Current number of unhealed pressure injuries at each stage | COMPONENT | 1 |
| LP435000-7 | CMS - High risk drug classes - use and indication | COMPONENT | 1 |
| LP435001-5 | CMS - Header - Special Treatments, Procedures, and Programs | COMPONENT | 1 |
| LP435002-3 | CMS - Special Treatments, Procedures, and Programs | COMPONENT | 1 |
| LP435003-1 | CMS - Header - Participation in Assessment and Goal Setting | COMPONENT | 1 |
| LP435004-9 | CMS - Participation in assessment and goal setting | COMPONENT | 1 |
| LP435005-6 | CMS - Discharge Plan | COMPONENT | 1 |
| LP435006-4 | CMS - Return to Community | COMPONENT | 1 |
| LP435007-2 | CMS - Referral | COMPONENT | 1 |
| LP435008-0 | CMS - Referral has been made to the local contact agency | COMPONENT | 1 |
| LP435009-8 | CMS - Reason referral to local contact agency not made | COMPONENT | 1 |
| LP435010-6 | CMS - Correction Request | COMPONENT | 1 |
| LP435015-5 | Candida albicans+dubliniensis+parapsilosis+tropicalis DNA | COMPONENT | 1 |
| LP435016-3 | ECMO device | SYSTEM | 2 |
| LP435017-1 | CMS - Nutritional approaches - on admission | COMPONENT | 1 |
| LP435022-1 | TCRB gene and TCRG gene rearrangements | COMPONENT | 3 |
| LP435023-9 | Myeloid sarcoma analysis | COMPONENT | 1 |
| LP435024-7 | Cardiovascular risk panel | COMPONENT | 1 |
| LP435028-8 | Cells.CD3^after stimulation with SARS-CoV-2 Nucleocapsid peptide | COMPONENT | 1 |
| LP435029-6 | Cells.CD3+CD4+^after stimulation with SARS-CoV-2 Nucleocapsid peptide | COMPONENT | 1 |
| LP435030-4 | Cells.CD3+CD8+^after stimulation with Sars-CoV-2 nucleocapsid peptide | COMPONENT | 1 |
| LP435055-1 | Tetrazepam | COMPONENT | 1 |
| LP435056-9 | Nonspermatozoal cells | COMPONENT | 1 |
| LP435066-8 | Rhabdomyolysis and Metabolic myopathy multigene panel | COMPONENT | 1 |
| LP435105-4 | Number of falls | COMPONENT | |
| LP435110-4 | Particulate matter 10 | COMPONENT | |
| LP435111-2 | Particle matter 2.5 | COMPONENT | 1 |
| LP435136-9 | Hereditary Wilms tumor multigene analysis | COMPONENT | 1 |
| LP435137-7 | Somatotropin and glucose post glucose stimulation panel | COMPONENT | 1 |
| LP435142-7 | Prenatal hepatitis B and C panel | COMPONENT | 1 |
| LP435143-5 | Neonatal ABO, Rh and DAT panel | COMPONENT | 1 |
| LP435177-3 | 1-deoxysphinganine | COMPONENT | 1 |
| LP435187-2 | MTTP gene targeted mutation analysis | COMPONENT | 1 |
| LP435188-0 | MTTP gene | COMPONENT | |
| LP435189-8 | COL4A3 gene targeted mutation analysis | COMPONENT | 1 |
| LP435192-2 | Special investigation unit (SIU) medical record request | COMPONENT | 1 |
| LP435197-1 | SLC35A3 gene targeted mutation analysis | COMPONENT | 1 |
| LP435200-3 | SLC35A3 gene targeted mutation analysis | COMPONENT | |
| LP435201-1 | DNAI1 gene targeted mutation analysis | COMPONENT | 1 |
| LP435202-9 | DNAI1 gene targeted mutation analysis | COMPONENT | |
| LP435203-7 | COQ4 gene targeted mutation analysis | COMPONENT | 1 |
| LP435205-2 | COQ4 gene targeted mutation analysis | COMPONENT | |
| LP435206-0 | Nickel Ab.IgE | COMPONENT | 2 |
| LP435208-6 | Cancer staging after multimodality therapy | COMPONENT | 1 |
| LP435209-4 | Cancer staging after tumor recurrence | COMPONENT | 1 |
| LP435210-2 | Cancer staging during autopsy | COMPONENT | 1 |
| LP435211-0 | Tumor marker level | COMPONENT | 1 |